I. MODIFIED AGREEMENTS

Company*
(Country;
Symbol)

Company*
(Country;
Symbol)

Change from original agreement

Terms/Details (Date)


Enzo Biochem
Inc.
(NYSE:ENZ)

Digene Corp. (DIGE)

Entered a settlement and license agreement related to an Enzo patent on nucleic acid detection

The settlement involves payments to Enzo of $30.5M and the granting to Digene of a nonexclusive, royalty-bearing, worldwide license for use of the '581 family of patents (10/14)

ComGenex
Inc.*
(Hungary)

Echelon Biosciences Inc.*

Echelon got rights to acquire ComGenex's share of intellectual property from their drug discovery collaboration

Echelon can secure exclusive rights to joint IP by making up-front and milestone payments; they also will explore additional discovery programs in cancer (10/25)

Immunomedics
Inc.
(IMMU)

Cytogen Corp. (CYTO) and C.R. Bard Inc.

They settled a patent suit that claimed Cytogen's ProstaScint infringed an Immunomedics patent

The settlement included an undisclosed payment to Immunomedics with no admission of fault or liability (9/29)

MonoGen Inc.*

Molecular Diagnostics Inc. (OTC BB:MCDG)

MDI subsidiary AccuMed International Inc. and MonoGen settled a license dispute on technologies for monitoring and diagnosing cancer

As part of the settlement, AccuMed assigned to MonoGen all the AccuMed patents and know-how covering the subject; MDI got a nonexclusive license covering some of its products that use fluorescent probes (10/18)

Seattle
Genetics Inc.
(SGEN)

Genentech Inc. (NYSE:DNA)

Genentech is designating additional antigen targets under their collaboration on antibody-drug conjugates

Seattle Genetics gets a $1.6M access fee and remains eligible for milestone and royalty payments (11/9)

XOMA Ltd.
(XOMA)

Millennium Pharmaceuticals Inc. (MLNM)

They restructured November 2001 deal for development of MLN2222, which is in Phase I trials for coronary artery bypass graft surgery

XOMA opted to work under a milestone and royalty arrangement rather than sharing costs and profits; XOMA will be responsible for work through Phase I, instead of Phase II; Millennium's stock purchase obligations ended (10/12)

II. TERMINATED AGREEMENTS

Xenova
Group plc
(UK; XNVA)

Millennium Pharmaceuticals Inc. (MLNM)

Millennium will stop funding the XR5944/XR11576 program in cancer after completion of ongoing Phase I trials

Millennium has been the North American partner on the program since 2001, and paid $11.5M up front in the deal; Xenova will decide the program's future after Phase I data are in (11/16)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.